Remedy Robotics Raises $62 Million Series B to Bring Life-Saving Cardiovascular Intervention to Patients Everywhere
<p>Funding will support clinical trials, advancement toward FDA approval, and planned commercial deployment of the company's AI-enabled endovascular robotic platform and software suite SAN FRANCISCO, Nov. 16, 2026 /PRNewswire/ -- Remedy Robotics, Inc. ("Remedy"), a leading healthcare and...</p>
Read original article ↗